CN Patent

CN116194456B — 作为kras抑制剂的杂环化合物的制备及其应用方法

Assigned to KECHOW PHARMA Inc · Expires 2025-08-29 · 1y expired

What this patent protects

式(I)的化合物或其药学上可接受的盐、前药、互变异构体或立体异构体和溶剂化物，这类化合物可用于治疗哺乳动物中癌症和炎症。还公开了式(I)化合物的制备方法以及包含所述化合物的药物组合物。

USPTO Abstract

式(I)的化合物或其药学上可接受的盐、前药、互变异构体或立体异构体和溶剂化物，这类化合物可用于治疗哺乳动物中癌症和炎症。还公开了式(I)化合物的制备方法以及包含所述化合物的药物组合物。

Drugs covered by this patent

Krazati (ADAGRASIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN116194456B
Jurisdiction: CN
Classification: —
Expires: 2025-08-29
Drug substance claim: No
Drug product claim: No
Assignee: KECHOW PHARMA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.